Trial Profile
A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Exercise Tolerance in Subjects With Chronic Stable Angina.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- 06 Dec 2012 Actual initiation date changed from Apr 2012 to Jul 2012 as reported by ClinicalTrials.gov.
- 01 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.